Business
Medicenna Amends Protocol of Phase 2b Recurrent Glioblastoma Study of MDNA55 in Response to Strong Safety Data and Early Efficacy Read-outs
Medicenna Amends Protocol of Phase 2b Recurrent Glioblastoma Study of MDNA55 in Response t...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Amends Protocol of Phase 2b Recurrent Glioblastoma Study of MDNA55 in Response to Strong Safety Data and Early Efficacy Read-outs\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, May 2, 2018\n\n\n\nTORONTO and HOUSTON, May 2, 2018 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA, OTCQX: MDNA), a clinical stage immunotherapy company, announced today that half the patients in the ongoing Phase 2b study of MDNA55 in recurrent glioblastoma (rGBM) have been recruited and the data to date demonstrate solid safety results and early signals of efficacy based on the findings of the Safety Review and Clinical Advisory Committees, comprised of key opinion leaders and study investigators. \n\nMDNA55 is a novel first in class Interleukin-4 empowered cytokine (IL4-EC). This proprietary targeted therapy is designed to harness the exceptional specificity and affinity of engineered cytokines to selectively and simultaneously deliver cell killing payloads to the bulk tumor, tumor microenvironment (TME) and cancer stem cells (CSC). MDNA55 is administered directly into brain tumors using a technique known as Convection Enhanced Delivery (CED), which allows precision delivery of MDNA55 at high concentrations into the tumor tissue while avoiding exposure to the rest of the body. The clinical trial is currently enrolling adult patients with rGBM at leading brain cancer centers in the US.\n\n\"We are pleased with the safety profile to date and early efficacy signals of MDNA55. We are amending the protocol at the recommendation of our clinical advisors to further improve the chances for demonstrating increased therapeutic benefit for patients living with this life-threatening disease,\" said Fahar Merchant, PhD, President and Chief Executive Officer of Medicenna.\n\nPrincipal Investigator, John H. Sampson MD, PhD, of Duke University Medical Center Department of Neurosurgery, commented, \"The study has contributed substantially to the improvement of Convection Enhanced Delivery of drugs directly into brain ...